TROP2 normalized membrane ratio proposed as predictor for Dato-DXd in NSCLC
Stephen V Liu highlighted a Nature Medicine paper using digital pathology to score TROP2 internalisation, rather than expression alone, as a predictor for Dato-DXd in non-small cell lung cancer.
“Computational pathology approach using digital pathology to assess internalization, not just expression.”— Stephen V Liu, MD
Stephen V Liu, a thoracic oncologist, wrote on X about a paper published in Nature Medicine. The paper examines the normalized membrane ratio (NMR) of TROP2, measured by quantitative continuous scoring (QCS), as a predictor for Dato-DXd, a TROP2 ADC, in non-small cell lung cancer (NSCLC).
According to Liu, the work uses a computational pathology approach. It applies digital pathology to assess internalisation, not just expression, of the target.
Liu's post is a brief summary and links to the paper. It does not report study results, patient numbers or outcomes, so those details cannot be confirmed from the post alone.
Liu's X profile describes him as Chief of Hematology & Oncology at Georgetown and MedStar Georgetown University Hospital, and Head of Developmental Therapeutics at the Lombardi Comprehensive Cancer Center.
Original source
“Computational pathology approach using digital pathology to assess internalization, not just expression.”
— Stephen V Liu, MD View the post on X
